Mupirocin

Mupirocin is prescribed to treat:

• Bacterial skin infections like impetigo • Various related conditions in the dermatology category • Associated symptoms and complications

It is an important medication that helps manage these conditions effectively.

Mupirocin (Bactroban, Centany) is a topical antibiotic used for impetigo, minor skin infections, secondarily infected wounds, and — importantly — nasal decolonisation of Staphylococcus aureus including MRSA. Its unusual mechanism means it does not share resistance with any systemic antibiotic class.

Mechanism of Action

Mupirocin reversibly binds bacterial isoleucyl-tRNA synthetase, the enzyme that attaches isoleucine to its transfer RNA. Blocking it halts incorporation of isoleucine into proteins, arresting protein synthesis and RNA synthesis.

This target is not shared by any other clinically used antibiotic class, which has two consequences. There is no cross-resistance with beta-lactams, macrolides, tetracyclines, or fluoroquinolones — so mupirocin remains effective against organisms resistant to those. And the bacterial enzyme differs sufficiently from the human equivalent that mupirocin is selectively toxic to bacteria.

It is bacteriostatic at low concentrations and bactericidal at the high concentrations achieved topically, and it is active against Gram-positive organisms including Staphylococcus aureus, MRSA, and Streptococcus pyogenes — precisely the organisms that cause most superficial skin infection.

Mupirocin is inactivated rapidly if absorbed systemically, which is why it is a topical-only agent. That property gives it an excellent safety profile with negligible systemic effects, and it also means it cannot be used for anything beyond the skin surface and nasal mucosa.

The polyethylene glycol vehicle in the ointment is absorbed and can accumulate in significant renal impairment when applied to large open wounds, which is the one systemic caution.

Clinical Use

Mupirocin is first-line for impetigo, where topical treatment is as effective as oral antibiotics for localised disease and avoids systemic exposure entirely. Extensive impetigo, or disease with systemic features, needs oral therapy such as cephalexin.

It is used for small infected cuts, abrasions, and folliculitis. It is not appropriate for cellulitis, which involves deeper tissue that a topical agent cannot reach — a distinction that matters, because treating spreading cellulitis with an ointment delays effective treatment while infection advances.

Its most distinctive role is nasal decolonisation. The anterior nares are the principal reservoir of S. aureus carriage, and intranasal mupirocin eradicates it in most carriers. This is used before certain surgical procedures — cardiac and orthopaedic in particular — where it reduces surgical site infection, and in managing recurrent staphylococcal skin infection, often combined with chlorhexidine washes.

Recurrent boils and abscesses are a common reason patients present repeatedly, and decolonisation of the patient and sometimes household members addresses the reservoir rather than each episode. This is worth considering in anyone with a third or fourth episode. Our dermatologic team manages recurrent skin infection, and the CDC MRSA resource covers prevention.

Resistance

Mupirocin resistance is real and has emerged in direct proportion to how widely the drug is used, which shapes how it should be prescribed.

Low-level resistance arises from mutations in the native enzyme; high-level resistance comes from a plasmid-borne gene encoding an alternative synthetase that mupirocin cannot bind, and it confers complete failure.

Rates have risen in settings where mupirocin has been used extensively and indiscriminately — long-term care facilities and dialysis units among them — and prolonged or repeated courses select for it.

The practical implications are that courses should be short and defined, typically five to ten days, that mupirocin should not be used as a general-purpose wound ointment applied indefinitely, and that decolonisation should be targeted at people who will benefit rather than applied broadly. Failure of decolonisation should prompt consideration of resistance rather than a longer course. The MedlinePlus mupirocin entry covers prescribing detail.

Monitoring and Follow-Up

No laboratory monitoring is required. Clinical response is the measure: impetigo should improve within three to five days.

Failure to improve raises several possibilities — resistance, a wrong diagnosis, deeper infection requiring systemic therapy, or an underlying condition such as eczema that is perpetuating skin breakdown. Impetiginised eczema needs the eczema treated as well as the infection, and treating only the bacteria leads to prompt recurrence.

Local irritation, burning, and itching are the usual adverse effects and are generally mild. Contact sensitisation occurs occasionally, more often to the vehicle than to mupirocin itself.

For nasal decolonisation, a defined course is applied to both nares, and confirmation of eradication is not routinely required outside specific settings.

Special Populations

In pregnancy, mupirocin's negligible systemic absorption makes it acceptable, and it is compatible with breastfeeding — though it should not be applied to the nipple immediately before feeding.

In children it is widely used for impetigo, which is common at school age, and children with impetigo can usually return to school 24 to 48 hours after starting treatment with lesions covered.

In significant renal impairment, the ointment should not be applied to large open wounds because of polyethylene glycol absorption; the cream formulation uses a different vehicle and avoids this. Mupirocin should not be used in the eyes.

One point on how it is dispensed. Mupirocin is prescription-only in the United States, unlike the over-the-counter triple-antibiotic ointments containing neomycin, bacitracin, and polymyxin. Those are widely used on minor wounds and are a common cause of allergic contact dermatitis — neomycin in particular is among the more frequent contact allergens — which then looks like a worsening infection and prompts more of the same ointment. A wound that becomes redder, itchier, and more sharply demarcated on a triple-antibiotic ointment is usually reacting to it rather than becoming infected.

When to Contact Your Doctor

Report spreading redness, warmth, swelling, or streaking from a treated area, or fever — these indicate cellulitis or systemic infection requiring oral or intravenous antibiotics rather than a topical agent.

Report failure to improve within three to five days. Report increasing pain, or a lesion that becomes fluctuant, which may indicate an abscess needing drainage — drainage is the treatment for an abscess, and no antibiotic substitutes for it.

Report recurrent boils or skin infections rather than treating each episode separately; that pattern usually means a reservoir that decolonisation can address.

Report significant burning, itching, or a worsening rash at the application site, which may indicate a reaction to the preparation.

To address a skin infection that is not improving, discuss recurrent infections, or plan decolonisation, contact us or schedule a visit.